NORTH AMERICA SEPSIS DIAGNOSTICS MARKET FORECAST 2021-2028

The North America sepsis diagnostics market is projected to progress with a CAGR of 7.87%, over the forecasted years, 2021-2028. The region’s market growth is accredited to key factors, such as, the well-established healthcare infrastructure, the favorable medical reimbursement scenario, and the high adoption rate of sepsis diagnostic instruments across diagnostic centers and laboratories. 

north-america-sepsis-diagnostics-market

The North America sepsis diagnostics market growth is determined by assessing the United States and Canada. As per the statistics issued by the Centers for Disease Control and Prevention (CDC), nearly 1.7 million adults develop sepsis in the United States, annually. Sepsis-related cases in the country continue to rise, owing to factors like the increasing geriatric populace, the prevalence of infections incurable by antibiotics, and the higher disease-risk in patients that have undergone an organ transplant. As a medical condition requiring more effective diagnosis, sepsis also demands extreme sensitivity and rapid test speed, with a short turnaround time (TAT).

On the other hand, the National Institutes of Health supports numerous studies concentrated on sepsis, analyzing multiple potential treatments for the condition. The CDC launched an educational initiative termed, ‘Get Ahead of Sepsis,’ in order to protect Americans from the impact of sepsis. The initiative encourages healthcare professionals to educate patients, diagnose and identify the disease early, prevent infections, and begin the necessary treatments. Hence, these aspects are set to propel the sepsis diagnostics market growth in the United States, over the forecast period.

Luminex Corporation, headquartered in the United States, develops, manufactures, and markets biological testing products and technologies. The company is operational across North America, the Asia-Pacific, and Europe. Its assay product segment constitutes gastrointestinal pathogen detection, respiratory viral panel (RVP), cystic fibrosis, multiCode assays and products, and pharmacogenetics products, among others.

TABLE OF CONTENTS
  1. RESEARCH SCOPE & METHODOLOGY
    1. STUDY OBJECTIVES
    2. SCOPE OF STUDY
    3. METHODOLOGY
    4. ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    1. MARKET SIZE & ESTIMATES
    2. MARKET OVERVIEW
  3. MARKET DYNAMICS
    1. KEY DRIVERS
      1. PREVAILING BURDEN OF SEPSIS
      2. COMPLICATIONS ARISING DUE TO HOSPITAL-ACQUIRED INFECTIONS (HAIS)
      3. SPREAD OF INFECTIOUS DISEASES AUGMENTING SEPSIS PROCEDURES
      4. SURGING GOVERNMENT INITIATIVES
    2. KEY RESTRAINTS
      1. COMPLICATIONS ASSOCIATED WITH THE REIMBURSEMENT POLICIES
      2. HIGH COST OF AN AUTOMATED DIAGNOSTICS INSTRUMENT
  4. KEY ANALYTICS
    1. IMPACT OF COVID-19 ON SEPSIS DIAGNOSTICS MARKET
    2. KEY INVESTMENT INSIGHTS
    3. PORTER’S FIVE FORCES ANALYSIS
      1. BUYERS POWER
      2. SUPPLIERS POWER
      3. SUBSTITUTION
      4. NEW ENTRANTS
      5. INDUSTRY RIVALRY
    4. OPPORTUNITY MATRIX
    5. VENDOR LANDSCAPE
  5. MARKET BY TECHNOLOGY
    1. MICROBIOLOGY
    2. IMMUNOASSAY
    3. MOLECULAR DIAGNOSTICS
    4. OTHER TECHNOLOGIES
  6. MARKET BY DIAGNOSTIC METHOD
    1. CONVENTIONAL DIAGNOSTICS
    2. AUTOMATED DIAGNOSTICS
  7. MARKET BY PRODUCT
    1. BLOOD CULTURE MEDIA
    2. ASSAY KITS & REAGENTS
    3. INSTRUMENTS
  8. MARKET BY PATHOGEN
    1. GRAM - POSITIVE AND GRAM - NEGATIVE BACTERIAL SEPSIS
    2. FUNGAL SEPSIS
    3. OTHER PATHOGENS
  9. MARKET BY TESTING TYPE (IN TERMS OF REVENUE: $ MILLION)
    1. LABORATORY TESTING
    2. POINT-OF-CARE TESTING
  10. GEOGRAPHICAL ANALYSIS
    1. NORTH AMERICA
      1. MARKET SIZE & ESTIMATES
      2. KEY GROWTH ENABLERS
      3. KEY CHALLENGES
      4. KEY PLAYERS
      5. COUNTRY ANALYSIS
        1. UNITED STATES
        2. CANADA
  11. COMPETITIVE LANDSCAPE
    1. KEY STRATEGIC DEVELOPMENTS
      1. MERGERS & ACQUISITIONS
      2. PRODUCT LAUNCHES & DEVELOPMENTS
      3. PARTNERSHIPS, CONTRACTS/AGREEMENTS & COLLABORATIONS
      4. BUSINESS EXPANSIONS/ APPROVALS/ ANNOUNCEMENTS
    2. COMPANY PROFILES
      1. ABBOTT LABORATORIES
      2. BECTON, DICKINSON AND COMPANY
      3. BIOMERIEUX SA
      4. BRUKER CORPORATION
      5. CYTOSORBENTS
      6. DANAHER
      7. EKF DIAGNOSTICS
      8. F. HOFFMANN-LA ROCHE
      9. IMMUNEXPRESS INC
      10. LUMINEX CORPORATION
      11. RESPONSE BIOMEDICAL CORPORATION
      12. T2 BIOSYSTEMS INC
      13. THERMO FISHER SCIENTIFIC INC
LIST OF TABLES

TABLE 1: MARKET SNAPSHOT - SEPSIS DIAGNOSTICS

TABLE 2: NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 3: NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 4: NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY DIAGNOSTIC METHOD, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 5: NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY DIAGNOSTIC METHOD, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 6: NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 7: NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 8: NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 9: NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 10: GRAM-NEGATIVE BACTERIA CAUSING SEPSIS

TABLE 11: GRAM-POSITIVE BACTERIA CAUSING SEPSIS

TABLE 12: NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY TESTING TYPE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 13: NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY TESTING TYPE, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 14: NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 15: NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 16: LEADING PLAYERS OPERATING IN NORTH AMERICA SEPSIS DIAGNOSTICS MARKET

TABLE 17: LIST OF MERGERS & ACQUISITIONS

TABLE 18: LIST OF PRODUCTS LAUNCHES & DEVELOPMENTS

TABLE 19: LIST OF PARTNERSHIPS & AGREEMENTS

TABLE 20: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

LIST OF FIGURES

FIGURE 1: KEY INVESTMENT INSIGHTS

FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

FIGURE 3: OPPORTUNITY MATRIX

FIGURE 4: VENDOR LANDSCAPE

FIGURE 5: NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, IN 2020

FIGURE 6: NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY MICROBIOLOGY, 2021-2028 (IN $ MILLION)

FIGURE 7: NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY IMMUNOASSAY, 2021-2028 (IN $ MILLION)

FIGURE 8: NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY MOLECULAR DIAGNOSTICS, 2021-2028 (IN $ MILLION)

FIGURE 9: NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY OTHER TECHNOLOGIES, 2021-2028 (IN $ MILLION)

FIGURE 10: NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY DIAGNOSTIC METHOD, IN 2020

FIGURE 11: NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY CONVENTIONAL DIAGNOSTICS, 2021-2028 (IN $ MILLION)

FIGURE 12: NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY AUTOMATED DIAGNOSTICS, 2021-2028 (IN $ MILLION)

FIGURE 13: NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, IN 2020

FIGURE 14: NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY BLOOD CULTURE MEDIA, 2021-2028 (IN $ MILLION)

FIGURE 15: NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY ASSAY KITS & REAGENTS, 2021-2028 (IN $ MILLION)

FIGURE 16: NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY INSTRUMENTS, 2021-2028 (IN $ MILLION)

FIGURE 17: NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN, IN 2020

FIGURE 18: NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY GRAM - POSITIVE AND GRAM - NEGATIVE BACTERIAL SEPSIS, 2021-2028 (IN $ MILLION)

FIGURE 19: NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY FUNGAL SEPSIS, 2021-2028 (IN $ MILLION)

FIGURE 20: NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY OTHER PATHOGENS, 2021-2028 (IN $ MILLION)

FIGURE 21: NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY TESTING TYPE, IN 2020

FIGURE 22: NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY LABORATORY TESTING, 2021-2028 (IN $ MILLION)

FIGURE 23: NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, BY POINT-OF-CARE TESTING, 2021-2028 (IN $ MILLION)

FIGURE 24: NORTH AMERICA SEPSIS DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)

FIGURE 25: UNITED STATES SEPSIS DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)

FIGURE 26: CANADA SEPSIS DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)

Request For A Free Sample